Date: 2016-02-03
Type of information: Nomination
Compound:
Company: Maxivax (Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On February 3, 2016 , MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, announced the appointment of Dimitrios Goundis Ph.D., as its Chief Executive Officer. Dimitrios Goundis has over 25 years of experience in the life science sector. Since 2009 he worked for The Medicines Company both in the US and in Europe, in various senior roles, including Business Development and Global Head of Research &
Development. From 2000-2008 he was with Speedel in Basel, Switzerland, where he became Chief Operating Officer (COO). Prior to that he held senior project management and research scientist positions at F. Hoffman-La Roche in Basel, including immunology, oncology and the central nervous system. Dimitrios was awarded his PhD in Biochemistry from the University of Oxford, a BSc (Hons) in Chemistry and Biochemistry from the University of London, and acertificate in investment management from the London Business School.
Financial terms:
Latest news:
